Full Press Release Details
Professor Lea payen is an expert in molecular biology and toxicology and is leading the collaboration between Hospital of Lyon and Volition, to validate Volition’s biomarker test .
This collaboration is a part of our strategy to attain certification under the In Vitro Diagnostic Regulation (IVDR), while also engaging industry leaders in the development and adoption of our transformative Nucleosomics™ technology in a range of exemplifications of our assays.
Working with centres of excellence, such as the Hospital of Lyon, and providing leading clinicians and researchers with exclusive, early access to our Nu.Q ® product range, is an enormous step forward for Volition and a critical phase in our path to commercialization. Professor Payen’s team has been working on validating our Nucleosomics™ technology, focusing on its efficacy in lung cancer and NETosis.
Watch our video to learn more:
Related Articles
• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states
Data Showing the Prognostic Value of its Nu.Q® Cancer Test
Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states
• Share
• Tweet
• Share on Facebook
• Share
Subscribe for Volition product updates .
Or, click here for Investor Updates and press releases .
" * " indicates required fields